



Patent
Attorney Docket No. 033572-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

William P. Spencer et al.

Application No.: 10/805,386

Filing Date: March 22, 2004

Title: ESTERIFIED FATTY ACID COMPOSITION

Group Art Unit: 1614

Examiner: Unassigned

Confirmation No.: 1731

FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.


The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By


Deborah H. Yellin
Registration No. 45,904

Date: February 11, 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|-----------------------------|---|------------------------|
| In re Patent Application of |) | |
| William P. Spencer et al. |) | Group Art Unit: 1614 |
| Application No.: 10/805,386 |) | Examiner: Unassigned |
| Filed: March 22, 2004 |) | Confirmation No.: 1731 |
| For: ESTERIFIED FATTY ACID |) | |
| COMPOSITION |) | |

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.


I, the undersigned, hereby state that no item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three (3) months prior to the filing of this Information Disclosure Statement.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date February 11, 2005

By: 
Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

VA 693947.1

(use as many sheets as necessary)

1

of

2

| |
|------------|
| 033572-001 |
|------------|

[illegible][illegible]

| Examiner Initials | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
|-------------------|---|
| | PERNEGER et al, "Risk of Kidney Failure Associated with the Use of Acetaminophen, Aspirin, and Nonsteroidal Antiinflammatory Drugs", <i>The New England Journal of Medicine</i> , December 22, 1994, Volume 331:1675-1679, Number 25; Massachusetts Medical Society, Boston, Massachusetts. |
| | "Impact of Arthritis and Other Rheumatic Conditions 1997", MMWR, May 7, 1999, 48(17);349-353, Centers for Disease Control and Preventoin, Atlanta, Georgia. |
| | WILCOX et al., "Striking Prevalence of Over-the-Counter Nonsteroidal Anti-inflammatory Drug Use in Patients with Upper Gastrointestinal Hemorrhage", <i>Archives of Internal Medicine</i> , January 10, 1994, Vol. 154, No. 1, American Medical Association, Chicago, Illinois. |
| | CURTIS et al., " <i>n</i> -3 Fatty Acids Specifically Modulate Catabolic Factors Involved in Articular Cartilage Degradation", <i>J. Biol Chem</i> , January 14, 2000, Vol. 275, Issue 2, pp. 721-724, American Society for Biochemistry and Molecular Biology, Bethesda, Maryland. |

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | | |
|--|-------------------------------|---------------------------|
| Sheet 2 of 2 | Application Number | 10/805,386 |
| | Filing Date | March 22, 2004 |
| | First Named Inventor | William P. Spencer et al. |
| | Examiner Name | Unassigned |
| | Attorney Docket Number | 033572-001 |

NON-PATENT LITERATURE DOCUMENTS

| Examiner Initials | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
|-------------------|---|
| | EVERTS et al., "Cox-2-Specific Inhibitors – the Emergence of a New Class of Analgesic and Anti-inflammatory Drugs", <i>Clinical Rheumatology</i> , 2000, 19:331-43, Elsevier, Oxford, United Kingdom. |
| | KREMER, Effects of Modulation of Inflammatory and Immune Parameters in Patients with Rheumatic and Inflammatory Disease Receiving Dietary Supplementation of n-3 and n-6 Fatty Acids, <i>Lipids</i> , 1996, 31 Supp: S-243-S-247, American Oil Chemists Society, Chicago, Illinois. |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.